kinetabio.com - קצב צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים KA

The development of immune activation agents is constrained by patents and the immense financial risks associated with early-stage testing. The 12-month revenue trajectory illustrates current dynamics, where the actual level equals 0.00. Kineta, Inc. (KA) seeks to confirm the efficacy of its anti-tumor drugs, yet the suspension of research to cut costs and uncertainty regarding management's actions cast doubt on the assets' ability to recover from the crisis.
פילוחי נתונים אנליטיים מרוכזים עבור Kineta (KA)

To assess the asset quality of Kineta, Inc. (KA), it is critical to track revenue scaling rates amid the outsourcing of antibody production. By analyzing year-over-year sales dynamics over the last four quarters, an investor can observe the daily price action of turnover over twelve months, enabling the timely identification of capital freeze risks in inventories should the company's liquidity levels prove insufficient.